{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:38:20Z","timestamp":1776087500270,"version":"3.50.1"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.1213","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T23:10:13Z","timestamp":1391209813000},"page":"233-237","source":"Crossref","is-referenced-by-count":26,"title":["Hypophosphatemic Osteomalacia Due to Drug-induced Fanconi's Syndrome Associated with Adefovir Dipivoxil Treatment for Hepatitis B"],"prefix":"10.2169","volume":"53","author":[{"given":"Hiroyuki","family":"Eguchi","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehisa","family":"Tsuruta","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Tani","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiichiro","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Hiromatsu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Kurume University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 282: 2305-2312, 1999."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Marcellin P, Chang TT, Lim SG, et al; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348: 808-816, 2003.","DOI":"10.1056\/NEJMoa020681"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800-807, 2003.","DOI":"10.1056\/NEJMoa021812"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48: 750-758, 2008.","DOI":"10.1002\/hep.22414"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743-1751, 2006.","DOI":"10.1053\/j.gastro.2006.09.020"},{"key":"6","unstructured":"6. Izzedine H, Hulot JS, Launay-Vacher V, et al; Adefovir Dipivoxil International 437 Study Group, Adefovir Dipivoxil International 438 Study Group. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 66: 1153-1158, 2004."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 50: 727-734, 2009.","DOI":"10.1002\/hep.23044"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lee HJ, Choi JW, Kim TN, Eun JR. A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus. Korean J Hepatol 14: 381-386, 2011 (in Korean, Abstract in English).","DOI":"10.3350\/kjhep.2008.14.3.381"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Izzedine H, Kheder-Elfekih R, Housset P, Sarkozy C, Brocheriou I, Deray G. Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS 23: 544-545, 2009.","DOI":"10.1097\/QAD.0b013e32832407f7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tamori A, Enomoto M, Kobayashi S, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat 17: 123-129, 2009.","DOI":"10.1111\/j.1365-2893.2009.01160.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Minemura M, Tokimitsu Y, Tajiri K, et al. Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil. World J Hepatol 2: 442-446, 2010.","DOI":"10.4254\/wjh.v2.i12.442"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kwon SY, Ahn SY, Ko SY, et al. A case of osteomalacia related to adefovir in a patient with chronic hepatitis B. Korean J Gastroenterol 56: 117-120, 2010 (in Korean, Abstract in English).","DOI":"10.4166\/kjg.2010.56.2.117"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Jung YK, Yeon JE, Choi JH, et al. Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver 4: 389-393, 2010.","DOI":"10.5009\/gnl.2010.4.3.389"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawate H, Taketomi A, Watanabe T, et al. Hypophosphatemic osteomalacia as a long-term complication after liver transplantation. Transplantation 91: e6-e8, 2011.","DOI":"10.1097\/TP.0b013e3181fc4b55"},{"key":"15","unstructured":"15. Kishimoto Y, Okano T, Teshima R. Osteomalacia caused by antiviral drug for chronic hepatitis B: A case report. Orthopedics & Traumatology 60: 148-151, 2011 (in Japanese, Abstract in English)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Girgis CM, Wong T, Ngu MC, et al. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 45: 468-473, 2011.","DOI":"10.1097\/MCG.0b013e3181e12ed3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Law ST, Li KK, Ho YY. Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil is there a safe dose? J Clin Pharm Ther 37: 128-131, 2012.","DOI":"10.1111\/j.1365-2710.2011.01278.x"},{"key":"18","unstructured":"18. Li L, Dong GF, Zhang X, Xie YS. Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B. Nan Fang Yi Ke Da Xue Xue Bao 31: 1956, 2011 (in Chinese, Abstract in English)."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Fabbriciani G, de Socio GV, Massarotti M, Ceriani R, Marasini B. Adefovir induced hypophosphatemic osteomalacia. Scand J Infect Dis 43: 990-992, 2011.","DOI":"10.3109\/00365548.2011.581307"},{"key":"20","unstructured":"20. Tanaka M, Setoguchi T, Ishidou Y, et al. Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report. Diagn Pathol 7: 108, 2012."},{"key":"21","unstructured":"21. Kim du H, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab 31: 240-246, 2013."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Dai CL, Zhu M, Wang BP, et al. Prolonged adefovir therapy associated Fanconi syndrome and interstitial nephritis in hepatitis B. Intern Med J 42: 955-957, 2012.","DOI":"10.1111\/j.1445-5994.2012.02854.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shimohata H, Sakai S, Ogawa Y, Hirayama K, Kobayashi M. Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil. Clin Exp Nephrol 17: 147-148, 2013.","DOI":"10.1007\/s10157-012-0762-8"},{"key":"24","unstructured":"24. Wu C, Zhang H, Qian Y, Wang L, Gu X, Dai Z. Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. J Clin Pharm Ther 38: 321-326, 2013."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002.","DOI":"10.1210\/jc.2002-021105"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 44: 108-116, 2006.","DOI":"10.1002\/hep.21225"},{"key":"27","unstructured":"27. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133: 1445-1451, 2007."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45: 307-313, 2007.","DOI":"10.1002\/hep.21534"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44: 283-290, 2006.","DOI":"10.1016\/j.jhep.2005.10.018"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in HBV infection. Expert Opin Drug Saf 10: 809-818, 2011.","DOI":"10.1517\/14740338.2011.593507"},{"key":"31","unstructured":"31. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 32: 734-740, 2001."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56: 570-580, 1999.","DOI":"10.1124\/mol.56.3.570"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 299: 567-574, 2001.","DOI":"10.1016\/S0022-3565(24)29264-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Viganò M, Lampertico P, Dongiovanni P, et al. A drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination. J Hepatol 52 Supplement 1: S7, 2010.","DOI":"10.1016\/S0168-8278(10)60016-5"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB. Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J Pharmacol Exp Ther 314: 923-931, 2005.","DOI":"10.1124\/jpet.105.084301"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/3\/53_53.1213\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T18:50:27Z","timestamp":1746125427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/3\/53_53.1213\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.1213","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}